ISCO International Stem Cell CORP revenue, earnings and financials
For the quarter ended June 30, 2026, International Stem Cell CORP reported revenue of $2.68M (up 9.3% from a year earlier), net income of −$71.0K and diluted EPS of −$0.01; over the last four quarters revenue was $9.51M and net income −$582K; for the fiscal year ended December 2025 revenue was $9.10M, up 0.2% on the year before.
ISCO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $9.10M, gross profit n/a, operating income −$267K, net income −$418K (margin -4.6%), EPS −$0.05
- Fiscal year ended Dec 2024: revenue $9.09M, gross profit n/a, operating income −$68.0K, net income −$209K (margin -2.3%), EPS −$0.03
- Fiscal year ended Dec 2023: revenue $7.79M, gross profit n/a, operating income −$663K, net income −$131K (margin -1.7%), EPS −$0.02
- Fiscal year ended Dec 2022: revenue $8.18M, gross profit n/a, operating income −$183K, net income −$331K (margin -4.0%), EPS −$0.04
- Fiscal year ended Dec 2021: revenue $7.18M, gross profit n/a, operating income −$1.92M, net income −$899K (margin -12.5%), EPS −$0.11
ISCO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $2.68M (up 9.3% year over year), net income −$71.0K, EPS −$0.01
- Quarter ended Mar 31, 2026: revenue $2.32M (up 8.7% year over year), net income −$220K, EPS −$0.03
- Quarter ended Dec 31, 2025 (from the annual report): revenue $2.16M (down 11.9% year over year), net income −$348K, EPS −$0.03
- Quarter ended Sep 30, 2025: revenue $2.37M (up 8.7% year over year), net income $57.0K, EPS $0.00
- Quarter ended Jun 30, 2025: revenue $2.45M (up 5.0% year over year), net income $129K, EPS $0.01
- Quarter ended Mar 31, 2025: revenue $2.13M (up 0.0% year over year), net income −$256K, EPS −$0.03
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.45M (up 29.5% year over year), net income $11.0K, EPS $0.01
- Quarter ended Sep 30, 2024: revenue $2.18M (up 10.4% year over year), net income −$125K, EPS −$0.02
- Quarter ended Jun 30, 2024: revenue $2.33M (up 26.6% year over year), net income $119K, EPS $0.01
- Quarter ended Mar 31, 2024: revenue $2.13M (up 2.1% year over year), net income −$214K, EPS −$0.03
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.89M (down 22.3% year over year), net income −$458K, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue $1.97M (up 15.9% year over year), net income −$131K, EPS −$0.02
- Quarter ended Jun 30, 2023: revenue $1.84M (down 9.2% year over year), net income $492K, EPS $0.03
- Quarter ended Mar 31, 2023: revenue $2.09M (up 3.3% year over year), net income −$34.0K, EPS $0.00
- Quarter ended Dec 31, 2022 (from the annual report): revenue $2.43M (up 31.9% year over year), net income $23.0K, EPS $0.00
- Quarter ended Sep 30, 2022: revenue $1.70M (down 7.5% year over year), net income −$343K, EPS −$0.04
- Quarter ended Jun 30, 2022: revenue $2.03M (up 10.6% year over year), net income −$2.00K, EPS $0.00
- Quarter ended Mar 31, 2022: revenue $2.02M (up 21.8% year over year), net income −$9.00K, EPS $0.00
- Quarter ended Dec 31, 2021 (from the annual report): revenue $1.84M, net income −$351K, EPS −$0.04
- Quarter ended Sep 30, 2021: revenue $1.84M, net income −$165K, EPS −$0.02
ISCO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $8.00K, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $13.0K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $929K, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $332K, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.30M, share buybacks n/a
ISCO balance sheet
- Jun 30, 2026: cash n/a, total assets $5.06M, total liabilities $4.98M, shareholders' equity −$4.23M
- Mar 31, 2026: cash n/a, total assets $5.13M, total liabilities $5.05M, shareholders' equity −$4.22M
- Dec 31, 2025: cash n/a, total assets $4.82M, total liabilities $4.58M, shareholders' equity −$4.06M
- Sep 30, 2025: cash n/a, total assets $5.28M, total liabilities $4.76M, shareholders' equity −$3.78M
- Jun 30, 2025: cash n/a, total assets $5.55M, total liabilities $5.14M, shareholders' equity −$3.90M
- Mar 31, 2025: cash n/a, total assets $5.62M, total liabilities $5.41M, shareholders' equity −$4.09M
- Dec 31, 2024: cash n/a, total assets $5.17M, total liabilities $4.80M, shareholders' equity −$3.93M
- Sep 30, 2024: cash n/a, total assets $5.18M, total liabilities $4.92M, shareholders' equity −$4.04M
What is ISCO's revenue?
International Stem Cell CORP reported $9.51M of revenue over its last four quarters, through June 30, 2026.
Is ISCO profitable?
No. International Stem Cell CORP lost $582K over the last four quarters.
What is ISCO's EPS?
Diluted earnings per share over the last four quarters were −$0.07; −$0.01 in the latest quarter.